乳清乳酸β-lactolin对轻度认知障碍患者的认知表现的影响:一项随机,双盲,安慰剂对照试验
Kentaro Umeda1, Keiko Kobayashi1, Ayana Kanatome1
1Kirin Central Research Institute, Kirin Holdings Company Ltd., Kanagawa, Japan.
Nutritional neuroscience
|November 19, 2024
概括
这项研究发现,β-lactolin在轻度认知障碍 (MCI) 患者的认知功能整体上没有显著改善. 然而,它在延迟回忆和女性中显示出改善,这表明对特定认知方面的潜在益处.
科学领域:
- 神经科学是一个神经科学.
- 营养科学 营养科学
- 老年学是一门学科.
背景情况:
- 轻度认知障碍 (MCI) 是正常衰老和痴呆之间的过渡阶段.
- 早期干预对于管理MCI和可能延迟疾病进展至关重要.
- 饮食成分,如牛奶衍生,正在被探索它们的认知益处.
研究的目的:
- 为了评估β-乳素的长期影响,一种牛奶衍生的四甲,对MCI个体的认知功能.
- 用标准化认知测试来评估β-lactolin的疗效.
主要方法:
- 进行了一项为期24周的随机,双盲,安慰剂对照试验.
- 48名患有MCI (MMSE-J: 24-28,CDR: 0.5) 的参与者 (年龄≥50岁) 每天接受β-lactolin (1.8 mg) 或安慰剂.
- 主要结局包括迷你心理状态检查 (MMSE-J) 和蒙特利尔认知评估 (MoCA-J) 的分数.
主要成果:
- 在MMSE-J或MoCA-J得分中没有发现显著的群体间差异.
- 群体内部分析显示,在12周和24周的β-lactolin组中,MoCA-J延迟回忆显著改善.
- 在女性的亚组分析显示,在24周后,与β-lactolin一起,MoCA-J总得分显著改善.
结论:
- 与安慰剂相比,β-lactolin在MCI患者中没有显著改善整体认知功能.
- 延迟回忆和女性子组的显著改善表明潜在的有针对性的认知益处.
- 需要对更大的样本进行进一步的研究,以确认β-lactolin在MCI中的疗效.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Role of Neurotransmitters in Memory
446
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
446


